Akèy › Kasinòm epitelyal ovè › Texas › San Antonio
Etid klinik pou Kasinòm epitelyal ovè nan San Antonio, TX
4 etid pou Kasinòm epitelyal ovè ap chèche patisipan nan sit nan ak bò kote San Antonio (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Ap rekriteFaz 2
- Texas Oncology - San Antonio Medical Center - Research Drive /ID# 275090, San Antonio
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Ap rekriteEtid obsèvasyon
- The University of Texas Health Science Center at San Antonio, San Antonio
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
Ap rekriteFaz 3
- Research Site, San Antonio
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Ap rekriteFaz 1
- Context Investigational Site, San Antonio
- Context Investigational Site, San Antonio
Etid Kasinòm epitelyal ovè nan lòt vil
- Durham, NC8 etid
- Boston, MA8 etid
- New York City, NY7 etid
- San Diego, CA7 etid
- Chicago, IL7 etid
- Baltimore, MD6 etid
- Philadelphia, PA6 etid
- Cleveland, OH6 etid
- Houston, TX6 etid
- Minneapolis, MN5 etid
- Salt Lake City, UT5 etid
- Portland, OR5 etid
Lòt etid nan San Antonio
- Kansè Poumon ki pa ti selil59 etid
- Kansè nan tete47 etid
- Kansè kolorektal46 etid
- Kansè Metastatik44 etid
- Kansè (tout kalite)41 etid
- Obèsite40 etid
- Dyabèt Tip 237 etid
- Sipwa34 etid
- Kansè ovè31 etid
- Kansè pankreyas31 etid
- Kansè pwostat28 etid
- Kansè Endomèt27 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.